Aileron Therapeutics (ALRN) Stock Analysis

What Aileron Therapeutics does

Aileron Therapeutics, Inc. is a U.S.-based clinical-stage company specializing in chemoprotection oncology. Its primary therapeutic candidate, ALRN-6924, is currently being evaluated across multiple clinical trials for various cancer types. These include a Phase 1 trial for solid tumors and lymphoma, a Phase 2a clinical trial targeting peripheral T-cell lymphoma, and a Phase I trial for acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS). Furthermore, ALRN-6924 is involved in combination studies: a Phase 1b trial testing its efficacy with cytarabine (Ara-C) in patients with MDS, and a Phase 2a combination trial with palbociclib for individuals with tumors exhibiting MDM2 amplifications co-amplifications, as well as for those with p53-mutated small cell lung cancer (the latter having already completed its Phase 1b clinical assessment). The company maintains license agreements with institutions such as the Dana-Farber Cancer Institute, Harvard College, and Umicore Precious Metals Chemistry USA, LLC. Established in 2001, the Boston, Massachusetts-headquartered firm was originally known as Renegade Therapeutics, Inc. before rebranding to Aileron Therapeutics, Inc. in February 2007.

Key metrics

ETFs linked to ALRN

Broad-market and Healthcare sector ETFs an investor holding Aileron Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ALRN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Aileron Therapeutics?

Aileron Therapeutics trades under the ticker ALRN on NASDAQ.

Which exchange is ALRN listed on?

ALRN is listed on NASDAQ.

What sector does Aileron Therapeutics operate in?

Aileron Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ALRN in a portfolio?

PortView shows ALRN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.